Pivotal Research Group initiated a Buy rating on USANA Health Sciences, Inc. USNA with a $100 price target in a report issued Monday.
Analyst Timothy S. Ramey noted that the company remained “an attractive growth vehicle with impressive top line growth, cash of over $8.50 per share and no debt. Valuation at 12.7x EPS is modest and upside to our target is 25 percent.”
Ramey also claimed that “USANA is unique among MLMs – it is trading not far off its 52-week high of $92 set in October 2013. But other than its modest valuation versus historic growth, it has not been caught up in the “anti-MLM” thesis in a meaningful way.”
“The major risk to USANA is regulatory – both U.S. and Chinese. Nutritional supplements are highly regulated; the MLM sector is clearly under the microscope by the FTC and others. We are confident that the MLM model USANA operates is legal and ethical, around the world,” according to Ramey.
USANA Health Sciences, Inc. recently traded at $82.29, up 2.40 percent.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.